# #211  Breaking Down MASLD vs. MASH and the MAESTRO-NASH & ESSENCE Trials: Beyond Journal Club Segment

Page: https://stenobird.com/podcast/core-im-internal-medicine-podcast-60389/211-breaking-down-masld-vs-mash-and-the-maestro-nash-essence-trials-beyond-journal-club-segment
Text version: https://stenobird.com/podcast/core-im-internal-medicine-podcast-60389/211-breaking-down-masld-vs-mash-and-the-maestro-nash-essence-trials-beyond-journal-club-segment.md
Podcast: [Core IM | Internal Medicine Podcast](https://stenobird.com/podcast/core-im-internal-medicine-podcast-60389)
Published: 2026-06-29T09:05:11+00:00
Episode link: https://www.coreimpodcast.com/2026/06/29/breaking-down-masld-vs-mash-and-maestro-nash-essence-trials-beyond-journal-club-segment/
Audio file: https://pscrb.fm/rss/p/audio2.redcircle.com/episodes/d7b14cb4-5f5b-4fe0-9cb7-82e18910f184/stream.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/core-im-internal-medicine-podcast-60389/episodes/211-breaking-down-masld-vs-mash-and-the-maestro-nash-essence-trials-beyond-journal-club-segment
Duration seconds: 2020

## Resource

MASLD affects nearly one in three adults worldwide, yet many patients remain undiagnosed until advanced fibrosis or cirrhosis develops. So, which patients should clinicians actually be screening? When is a FIB-4 enough, and when should we move to elastography or hepatology referral? And are we finally entering an era where we can meaningfully treat MASH? In this Beyond Journal Club episode, we unpack the evolving language of steatotic liver disease and take a close look at two major trials: MAESTRO-NASH studying resmetirom, the first FDA-approved liver-directed therapy for MASH, and ESSENCE, evaluating semaglutide in biopsy-confirmed disease. Along the way, we explore what these biopsy-based histologic endpoints really mean, why placebo responses were surprisingly high , and whether improvements in steatohepatitis and fibrosis will ultimately translate into better clinical outcomes for patients. This episode is for clinicians trying to understand where the field is headed, which patients deserve closer attention, and how metabolic liver disease is increasingly becoming part of everyday primary care and hospital medicine. 🔹 Sponsor: Oakstone CME Use the code "CORE325" for 25% off: https://www.coreimpodcast.com/MKSAP 🔹 Transcript and Shownotes : 01:57 | Understanding MASLD as a Systemic Disease 05:45 | MASLD vs MASH vs Met-ALD: Spectrum Steatotic Liver Disease 08:55 | How to Screen for Fibrosis (FIB-4 & FibroScan) 16:15 | Lifestyle Treatment & Weight Loss Targets 19:00 | ESSENCE Trial: Semaglutide for MASH 21:58 | MAESTRO-NASH Trial: Resmetirom 27:27 | Future Treatments for MASH 30:51 | Key Takeaways for Clinicians Tags: CoreIM, Internal Medicine, Medical Education, Hepatology, Fatty Liver Disease, Metabolic Dysfunction Associated Steatohepatitis, Nonalcoholic Fa…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/core-im-internal-medicine-podcast-60389/episodes/211-breaking-down-masld-vs-mash-and-the-maestro-nash-essence-trials-beyond-journal-club-segment/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/core-im-internal-medicine-podcast-60389/211-breaking-down-masld-vs-mash-and-the-maestro-nash-essence-trials-beyond-journal-club-segment.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.